Armata plans AP-SA02 Phase 3 study for complicated S. aureus bacteremia

Armata said it was finalizing activities for a pivotal Phase 3 superiority study of AP-SA02 in complicated Staphylococcus aureus bacteremia, anticipated to start in the second half of 2026.